News
Moorfields Eye Charity appoints Louise Robertshaw as trustee
Louise Robertshaw has been appointed as a trustee at Moorfields Eye Charity. She will also chair the charity’s fundraising and communications committee. Louise has considerable experience working at a senior level and as a trustee at national charities including in...
£5 million award for world-leading research facilities within new eye health centre
The Sir Jules Thorn Charitable Trust has awarded £5 million to UCL in partnership with Moorfields Eye Charity and Moorfields Eye Hospital to support Oriel – a centre for advancing eye health, opening in 2027.
Study calls for thorough investigation of patients with early signs of retinal vascular disease
Patients with the eye condition Paracentral Acute Middle Maculopathy (PAMM) would benefit from further investigation, as their risk of heart attacks and strokes may be greater than previously shown, suggests a new study led by researchers at Moorfields Eye Hospital NHS Foundation Trust.
World-first artificial intelligence foundation model for eye care to supercharge global efforts to prevent blindness
Researchers at Moorfields Eye Hospital and UCL Institute of Ophthalmology (IoO) have developed an artificial intelligence (AI) system that has the potential to not only identify sight-threatening eye diseases but also predict general health, including heart attacks, stroke and Parkinson’s disease.
Landmark review of glaucoma treatment and research published by Moorfields-led team
Four world-leading experts, including Hari Jayaram and Gus Gazzard from Moorfields, have combined their knowledge with the findings from over 150 peer-reviewed study publications to produce a landmark paper published in the Lancet.
Eye scans detect signs of Parkinson’s disease up to seven years before diagnosis
A team led by Siegfried Wagner and Pearse Keane of Moorfields Eye Hospital and UCL Institute of Ophthalmology (and spanning UCL institutions) has identified markers that indicate the presence of Parkinson’s disease in patients on average seven years before clinical presentation.
First UK Direct Selective Laser Trabeculoplasty (DSLT) device placed at Moorfields
Following an internationally successful Randomised Controlled Trial (RCT) comparing the Direct Selective Laser Trabeculoplasty (DSLT) with standard SLT, the first ever commercial device in the UK, the ‘Eagle’, has been installed and is in use at Moorfields Eye Hospital in London.
